本帖最后由 老马 于 2012-1-13 21:20 编辑 7 s( M! f+ y5 i
8 e; Z) `9 V& P% s0 v" U/ C# Y
爱必妥和阿瓦斯丁的比较
- t4 @& _. m8 p/ W |: L# h
* ^2 X) _" k# M
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
) `& n( a8 I" I. f# W
1 m- r! n* B6 O- b' w5 |) e
, ?* L$ ]$ Q3 \http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/8 ~5 K7 _; J3 D6 p4 r! j: m9 R
==================================================
6 V1 k# x% b. i1 WOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
5 X# p. l% q& xPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
. j9 m( a. I3 `) f4 Q3 IResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
) Z7 s# j+ I n3 K0 X L6 E
|
11011102001537 )
显身卡
, y& \7 Y# k8 ?6 P
